cmpd1

CMPD1 is a non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor(apparent Ki (Kiapp): 330 nM).

CMPD101 is a membrane-permeable small-molecule inhibitor of GRK2/3 (IC50: 18 nM and 5.4 nM). Which can be used for the study of heart failure. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively.

CMPD167 (MRK-1) is a potent, orally active inhibitor of CCR5 with significant in vitro antiviral efficacy [1].

CMPD101 hydrochloride is a membrane-permeable small molecule inhibitor of GRK2 and GRK3, exhibiting IC50 values of 18 nM and 5.4 nM, respectively. This compound also inhibits Rho-associated kinase 2 (ROCK-2) and PKCα, with IC50 values of 1.4 μM and 8.1 μM, respectively.

PRMT4-IN-1 is a selective inhibitor of PRMT4, demonstrating an IC50 value of 3.2 nM, and has been shown to reduce the relative viability of MCF7 cells [1].

Takeda103A (CMPD103A) is the GRK2-dependent bovine tubulin oxidation effective inhibitor.